Lee, Ho-Joon http://orcid.org/0000-0003-3616-5387
Kremer, Daniel M.
Sajjakulnukit, Peter
Zhang, Li
Lyssiotis, Costas A. http://orcid.org/0000-0001-9309-6141
Funding for this research was provided by:
U.S. Department of Education
American Association for Cancer Research (13-70-25-LYSS, 17-20-01-LYSS)
Damon Runyon Cancer Research Foundation (DFS-09-14)
V Foundation for Cancer Research (V2016-009)
Sidney Kimmel Foundation for Cancer Research (SKF-16-005)
National Cancer Institute (P30 CA046592)
National Institutes of Health (DK097153)
Charles Woodson Research Fund
University of Michigan Pediatric Brain Tumor Initiative
Article History
Received: 25 January 2019
Accepted: 20 June 2019
First Online: 9 July 2019
Compliance with ethical standards
:
: Costas A. Lyssiotis is an inventor on patents pertaining to Kras regulated metabolic pathways, redox control pathways in pancreatic cancer, and targeting GOT1 as a therapeutic approach. Ho‑Joon Lee, Daniel M. Kremer, Peter Sajjakulnukit and Li Zhang declare that they have no conflict of interest.
: This article does not contain any studies with human and/or animal participants performed by any of the authors.